Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)

 

Case Based Panel Discussion NSCLC – Does a Positive HER2 Mutation Effect Treatment Decisions?
dbrock
Author
Howard (Jack) West, MD
Image
For this round of case based panel discussions, Dr. Jack West is joined by Drs. Jonathan Riess and Suki Padda.

Jonathan W. Riess, MD MS is Associate Professor of Medicine in the Division of Hematology/Oncology at UC Davis Comprehensive Cancer Center. Sukhmani Padda MD is Assistant Professor of Medicine (Oncology) at the Stanford University Medical Center.

The doctors discuss a series of cases related to a diagnosis of NSCLC. In this video, the discussion is regarding a patient with a HER2 mutation, what is the clinical significance, and how does a positive HER2 mutation effect treatment decisions?

 

 

For a full listing of these case based discussions, please visit https://cancergrace.org/sponsor/case-based-panel-discussions-2019-lung-cancer.

To join the conversation, visit https://cancergrace.org/forum

Video Language

Next Previous link

Previous PostNext Post

Related Content

Online Community

A Brief Tornado.  I love the analogy Dr. Antonoff gave us to describe her presentation.  I felt it earlier too and am looking forward to going back for deeper dive.

Dr. Singhi's reprise about appropriate treatment, "Right patient, right time, right team".

 

An antibody–drug conjugate (ADC) works a bit like a Trojan horse. It has three main components:

  1. The antibody, which serves as the “horse,” specifically targets a protein found on cancer...

Bispecifics, or bispecific antibodies, are advanced immunotherapy drugs engineered to have two binding sites, allowing them to latch onto two different targets simultaneously, like a cancer cell and a T-cell, effectively...

The prefix “oligo–” means few. Oligometastatic (at diagnosis) Oligoprogression (during treatment)

There will be a discussion, “Studies in Oligometastatic NSCLC: Current Data and Definitions,” which will focus on what we...

Radiation therapy is primarily a localized treatment, meaning it precisely targets a specific tumor or area of the body, unlike systemic treatments (like chemotherapy) that affect the whole body.

The...

Biomarkers are genetic mutations (like EGFR, ALK, KRAS, BRAF) or protein levels (like PD-L1) in tumor cells that help guide personalized treatment, especially NSCLC, directing patients to targeted therapies or immunotherapies...

Recent Comments

JOIN THE CONVERSATION
Right patient, right time,…
By JanineT GRACE … on
A Brief Tornado.  I love the…
By JanineT GRACE … on
Biomarkers
By JanineT GRACE … on
Radiation Therapy
By JanineT GRACE … on